Thalidomide in multiple myeloma: Current status and future prospects

被引:57
作者
Cavenagh, JD [1 ]
Oakervee, H [1 ]
机构
[1] St Bartholomews & Royal London Sch Med & Dent, London, England
关键词
multiple myeloma; thalidomide; clinical management; thrombosis; neuropathy;
D O I
10.1046/j.1365-2141.2003.03902.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:18 / 26
页数:9
相关论文
共 50 条
[11]  
Durie BGM, 2001, BLOOD, V98, p163A
[12]  
Folkman J, 1974, Adv Cancer Res, V19, P331, DOI 10.1016/S0065-230X(08)60058-5
[13]   Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade [J].
Geitz, H ;
Handt, S ;
Zwingenberger, K .
IMMUNOPHARMACOLOGY, 1996, 31 (2-3) :213-221
[14]  
Grosbois B, 2001, BLOOD, V98, p163A
[15]   Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset [J].
Haslett, PAJ ;
Corral, LG ;
Albert, M ;
Kaplan, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (11) :1885-1892
[16]   Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy [J].
Hideshima, T ;
Chauhan, D ;
Shima, Y ;
Raje, N ;
Davies, FE ;
Tai, YT ;
Treon, SP ;
Lin, B ;
Schlossman, RL ;
Richardson, P ;
Muller, G ;
Stirling, DI ;
Anderson, KC .
BLOOD, 2000, 96 (09) :2943-2950
[17]   DORMANCY OF MICROMETASTASES - BALANCED PROLIFERATION AND APOPTOSIS IN THE PRESENCE OF ANGIOGENESIS SUPPRESSION [J].
HOLMGREN, L ;
OREILLY, MS ;
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (02) :149-153
[18]   Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma [J].
Juliusson, G ;
Celsing, F ;
Turesson, I ;
Lenhoff, S ;
Adriansson, M ;
Malm, C .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) :89-96
[19]  
Kropff MH, 2000, BLOOD, V96, p168A
[20]  
Lentzsch S, 2000, BLOOD, V96, p579A